Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination with Ipilimumab Versus Ipilimumab Alone in Patients with Advanced Refractory Melanoma (ILLUMINATE-301).
Journal of clinical oncology official journal of the American Society of Clinical Oncology（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined